Results 21 to 30 of about 1,113 (191)

Cost advantage of fluocinolone acetonide implant (ILUVIEN®) versus ranibizumab in the treatment of chronic diabetic macular oedema [PDF]

Global & Regional Health Technology Assessment, 2017
A cost analysis model was developed to evaluate the 3-year cost of treating vision impairment associated with chronic diabetic macular oedema (DMO) with either a single fluocinolone acetonide (FAc) implant or with 14 ranibizumab injections in the ...
Fahd Quhill, Annette Beiderbeck
doaj   +2 more sources

Fluocinolone Implant for Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis Syndrome: A Case Report

Case Reports in Ophthalmology, 2021
Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome is a rare and progressive disorder that predominantly affects both the eyes of young female individuals and can threaten visual function.
Lucía Moreno-Castro, Gerardo Pedro García-García, Joseba Artaraz, Alex Fonollosa   +3 more
doaj   +1 more source

Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double‐masked, vehicle‐controlled study

Acta Ophthalmologica, Volume 101, Issue 1, Page 22-33, February 2023., 2023
Abstract Purpose To evaluate topical dexamethasone ophthalmic suspension OCS‐01 (Oculis SA, Lausanne, Switzerland) in diabetic macular edema (DME). Methods This was a multicenter, double‐masked, parallel‐group, randomized, Phase 2 study. Patients aged 18–85 years with DME of <3 years duration, ETDRS central subfield thickness ≥ 310 μm by SD‐OCT, and ...
Einar Stefansson, Thorstein Loftsson, Michael Larsen, András Papp, Kai Kaarniranta, Marion R. Munk, Pravin Dugel, Ramin Tadayoni, DX‐211 study group   +8 more
wiley   +1 more source

Diabetic Macular Oedema Guidelines: An Australian Perspective

Journal of Ophthalmology, Volume 2023, Issue 1, 2023., 2023
The number of people living with diabetes is expected to rise to 578 million by 2030 and to 700 million by 2045, exacting a severe socioeconomic burden on healthcare systems around the globe. This is also reflected in the increasing numbers of people with ocular complications of diabetes (namely, diabetic macular oedema (DMO) and diabetic retinopathy ...
Yew Sen Yuen, Jagjit Singh Gilhotra, Michelle Dalton, Jaskirat S. Aujla, Hemal Mehta, Sanj Wickremasinghe, Gurmit Uppal, Jennifer Arnold, Fred Chen, Andrew Chang, Samantha Fraser-Bell, Lyndell Lim, Janika Shah, Ellie Bowditch, Geoffrey K. Broadhead, Paolo Milani   +15 more
wiley   +1 more source

Achieving Quiescence with Fluocinolone Implants

Case Reports in Ophthalmology, 2021
Persistent anterior uveitis causing cystoid macular oedema may necessitate either intraocular or systemic immunosuppression. This case report highlights how a newly licenced treatment, fluocinolone acetonide (Iluvien®, Alimera Sciences Ltd., England, UK)
Freia McGregor, Andrew D. Dick, Tomas Burke   +2 more
doaj   +1 more source

Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries [PDF]

, 2022
none14siIntroduction: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant delivers a continuous intravitreal corticosteroid dose for the treatment of refractory diabetic macular oedema (DMO). The aim of this study was to assess the impact of an
Arnould, Louis, Baillif, Stephanie, Barbosa-Breda, Joao, Bourredjem, Abderrahmane, Busch, Catharina, Creuzot-Garcher, Catherine, Gabrielle, Pierre-Henry, Grise-Dulac, Alice, Hamza, Mahmoud, Lebrize, Sarah, Lupidi, Marco, Mariotti, Cesare, Massin, Pascale, Rehak, Matus   +13 more
core   +3 more sources

Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti‐VEGF

Journal of Ophthalmology, Volume 2021, Issue 1, 2021., 2021
Background/Objectives. Currently, in England, antivascular endothelial growth factor (anti‐VEGF) is the first‐line treatment for diabetic macular oedema (DMO) where central macular thickness (CMT) is ≥400 microns. In pseudophakic eyes with suboptimal response to first‐line therapy, intravitreal corticosteroids may also be used.
Di Zou, Imran Jawaid, Winfried M. Amoaku, Marcel Menke   +3 more
wiley   +1 more source

Preserflo Microshunt Surgery for Ocular Hypertension following Intravitreal Fluocinolone Acetonide Implant Removal: A Case Report

Case Reports in Ophthalmology, 2022
Diabetic macular edema (DME) is now a well-known condition for which a number of treatments have been shown to be effective. Intraocular corticosteroids are part of this therapeutic arsenal but are sometimes responsible for ocular hypertension.
Amina Rezkallah, Olivier Loria, Thibaud mathis, Samuel Chacun, Philippe Denis, Laurent Kodjikian   +5 more
doaj   +1 more source

Ocular Pharmacokinetics of Fluocinolone Acetonide Following Iluvien Implantation in the Vitreous Humor of Rabbits [PDF]

Journal of Ocular Pharmacology and Therapeutics, 2015
Abstract Purpose: The purpose of this study was to evaluate the systemic and ocular pharmacokinetics (PK) of fluocinolone acetonide (FAc) following administration of Iluvien ® intravitreal implants.
Frances E, Kane, Kenneth E, Green
openaire   +2 more sources

Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]

, 2019
The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto, Greco A., La Cava M, Lambiase A, Limoli PG, Nebbioso M   +5 more
core   +1 more source